Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

RTOG 0831: Prostate Cancer

RTOG 0831: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE III TRIAL TO EVALUATE THE EFFECTIVENESS OF A PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL, IN PREVENTION OF ERECTILE DYSFUNCTION IN PATIENTS TREATED WITH RADIOTHERAPY FOR PROSTATE CANCER (PREVENTION OF ERECTILE DYSFUNCTION STUDY [PEDS])

Status: open and not enrolling

Approval Date: 12/31/1969

You are being asked to take part in this study because you have prostate cancer and as part of your treatment, you are receiving radiation therapy.
The purpose of this study is to compare the effects, both good and bad, of a drug, tadalafil, with a placebo (an inactive drug). Tadalafil is given as a treatment for erectile dysfunction (inability to maintain an erection long enough to engage in sexual intercourse). This study is being done to find out if tadalafil prevents erectile dysfunction in men with prostate cancer who are undergoing radiation therapy (that is, if the drug helps the participants taking it to maintain an erection following sexual stimulation). In this study, you will get tadalafil or placebo. You will not get both.


CTSU ECOG TAILORx PACCT-1: Breast Cancer

CTSU ECOG PACCT-1: PROGRAM FOR THE ASSESSMENT OF CLINICAL CANCER TESTS TRIAL ASSIGNING INDIVIDUALIZED OPTIONS FOR TREATMENT: THE TAILORx TRIAL

Status: open and not enrolling

Approval Date: 12/31/1969

The purpose of this clinical trial is to determine whether patients who have a tumor with an Oncotype DX Recurrence Score of 11-25 benefit from chemotherapy, and to confirm that most patients who have an Oncotype DX Recurrence score of less than10 have a very low risk of recurrence with hormonal therapy alone (no need for chemotherapy to reduce their risk of recurrence).  A second objective of this study is to create a tissue and blood specimen bank that includes specimens from all women who participate in the study, and to collect follow-up information regarding the health status of all women who participate in the study.  This will allow researchers to evaluate new diagnostic tests in the future that may predict benefits or side effects from certain treatments.


CTSU CALGB 90601: Transitional Cell / Bladder

CTSU CALGB 90601: A RANDOMIZED DOUBLE-BLIND PHASE III STUDY COMPARING GEMCITABINE, CISPLATIN, AND BEVACIZUMAB TO GEMCITABINE, CISPLATIN, AND PLACEBO IN PATIENTS WITH ADVANCED TRANSITIONAL CELL CARCINOMA

Status: open and enrolling

Approval Date: 12/31/1969

The purpose of this study is to compare the effects, both good and bad, of the combination of chemotherapy drugs gemcitabine and cisplatin with the combination of chemotherapy drugs gemcitabine, cisplatin, and the experimental drug bevacizumab on you and your urinary tract cancer (transitional cell cancer) and to find out which is better. Bevacizumab is an antibody that we think can block a protein called VEGF and inhibit the growth of new blood vessels. Bevacizumab has been approved by the FDA for the treatment of metastatic colorectal, lung, and breast cancer, but it is not FDA approved for transitional cell carcinoma and should be considered experimental. 


HLMCC0806: Breast Cancer

HLMCC0806: Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin®)

Status: open and enrolling

Approval Date: 12/31/1969

The purpose of this study is to compare the effects of an ACE inhibitor (lisinopril) or a beta-blocker (Coreg CR®) on heart function during treatment with trastuzumab (Herceptin®), a drug given as treatment for breast cancer.  Lisinopril and Coreg CR® are used to treat high blood pressure and heart failure in heart attack patients.  Study doctors want to find out which medication (lisinopril or Coreg CR®) is better at protecting heart function during treatment of breast cancer. The effect of the medicines will be compared to a placebo, which contains no active drug.  Patients will only get one of the study medicines – either lisinopril, Coreg CR® or placebo.  Study patients will keep a log of their use of the study drug, complete 4 quality of life questionnaires and monitor their blood pressure with a study supplied blood pressure cuff.